This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunomodulator.

An implantable drug delivery device and method for delivering a drug to a living body. The device includes a housing having at least one opening, a reservoir within the housing adapted to contain a drug, a temporary seal closing the opening of the housing, and a heating element in thermal contact with the temporary seal. The heating element is adapted to generate heat in response to a magnetic field to melt the temporary seal and release a drug within the reservoir through the opening of the housing.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

A delivery device may include a capsule housing, at least one tissue penetrating member in a sealed compartment in the capsule housing, wherein the at least one tissue penetrating member is configured to release a payload, and an actuator in the capsule housing and at least partially outside the sealed compartment, wherein the actuator is configured to advance the at least one tissue penetrating member out of the sealed compartment.

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

The present disclosure provides a method for producing a multifunctional implantable structure, the method having: preparing an implantable base; coating a polymer layer on the base, wherein the polymer layer is partially curable; curing the polymer layer such that the polymer layer has cured and non-cured portions; and dry-etching the polymer layer to remove the non-cured portion thereof, to allow the polymer layer to have a nano-turf structure having pores defined therein.

A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an integrin inhibitor. In particular, the disclosure features the topical treatment of sections and subsections of the gastrointestinal tract by integrin inhibitors (like vedolizumab) using an ingestible device that can detect its whereabouts in the Gl tract by using reflectance and which is programmed to release the drugs at a given site or proximal thereto, to treat gastrointestinal inflammatory diseases. The device has hardware storage devices with instructions on board to determine the location and release the formulations. Combination therapies are claimed as well in which the integrin inhibitor is added systemically and another agent (e.g. JAK inhibitor, TNF-alpha inhibitor or IL-12/IL-23 inhibitor) is added topically by means of the ingestible device. The topical administration is said to reduce the side effects associated with systemic treatment.

The present disclosure describes a method of delivering a therapeutic agent providing a microneedle array including a plurality of microneedles, the plurality of microneedles including a conductive coating disposed thereon, wherein the conductive coating includes the therapeutic agent and a conducting polymer; implanting the microneedle array in a dura mater of a subject in need thereof, wherein the microneedle array pierces the dura mater; and applying an electrical stimulus to the microneedle array to provide a controlled release of the therapeutic agent from the conductive coating, across the dura mater, to the central nervous system of the subject.